Abstract Number: L04 • 2019 ACR/ARP Annual Meeting
Cardiovascular Disease Risk in Calcium Pyrophosphate Deposition Disease
Background/Purpose: Calcium pyrophosphate deposition (CPPD) disease results from precipitation of calcium pyrophosphate (CPP) crystals in joints. Prior studies demonstrated that vascular calcification is more common…Abstract Number: 373 • 2019 ACR/ARP Annual Meeting
Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis
Background/Purpose: To identify prognostic factors and to assess the effects of immunosuppressive drugs on relapse risk in patients presenting with cardiac sarcoidosis (CS).Methods: From a…Abstract Number: 1895 • 2019 ACR/ARP Annual Meeting
Biologics Prevent Cardiovascular Events in Rheumatoid Arthritis by Inhibiting Non-calcified Coronary Plaque Progression and Stabilizing Vulnerable Plaques
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) may decrease cardiovascular events (CVE) in Rheumatoid arthritis (RA). We here evaluated whether bDMARDs reduce long-term CVE risk in…Abstract Number: 2676 • 2019 ACR/ARP Annual Meeting
Cardiovascular Treatment and the Incidence of Giant Cell Arteritis (GCA) – a Population-Based Case-Control Study
Background/Purpose: The aetiology of giant cell arteritis (GCA) is largely unknown. We aimed to evaluate ACE-inhibitors (ACE-i), angiotensin II receptor blockers (ARBs), beta-blocking agents, calcium…Abstract Number: 615 • 2019 ACR/ARP Annual Meeting
Effects of NSAIDs and TNF Inhibitors on Cardiovascular Events in Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Background/Purpose: Most studies show a significantly higher risk of myocardial infarction [MI] (odds ratio [OR] = 1.60) and stroke (OR = 1.50) in ankylosing spondylitis (AS)…Abstract Number: 2013 • 2019 ACR/ARP Annual Meeting
Increased Accumulation of Malondialdehyde-Acetaldehyde Modified HDL in Macrophage Without Decreased Cholesterol Efflux
Background/Purpose: Patients with rheumatoid arthritis (RA) are approximately two-fold more likely to develop cardiovascular disease (CVD). Prior reports have suggested that “dysfunctional” HDL may explain…Abstract Number: 2782 • 2019 ACR/ARP Annual Meeting
Comparative Risks of Cardiovascular Disease Among SLE Patients Receiving Immunosuppressive Medications
Background/Purpose: Human studies examining cardiovascular disease (CVD) risk associated with immunosuppressants (IS) have been limited, but mycophenolate mofetil (MMF) was shown to suppress vascular smooth muscle…Abstract Number: 622 • 2019 ACR/ARP Annual Meeting
Ten-year Atherosclerotic Cardiovascular Disease Risk Scores in Axial Spondyloarthritis versus the General Population: A Cross-sectional Study
Background/Purpose: Cardiovascular morbidity and mortality are increased in axial spondyloarthritis (axSpA). The 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend high intensity statin…Abstract Number: 2041 • 2019 ACR/ARP Annual Meeting
Epigenome-wide Association Study Reveals Differential DNA Methylation in Systemic Lupus Erythematosus Patients with a History of Ischemic Heart Disease
Background/Purpose: Patients with systemic lupus erythematosus (SLE) have an increased risk of ischemic heart disease (IHD). Altered methylation patterns have been reported both in SLE,…Abstract Number: 2867 • 2019 ACR/ARP Annual Meeting
Nocturnal Blood Pressure Dipping as a Marker of Endothelial and Cardiac Function in Pediatric-onset Systemic Lupus Erythematosus
Background/Purpose: There is a need for clinically useful measures of cardiovascular (CV) risk in pediatric-onset SLE (pSLE). Nocturnal blood pressure (BP) non-dipping (loss of the…Abstract Number: 805 • 2019 ACR/ARP Annual Meeting
Risk of Cardiovascular Disease in SLE Is Significant Early and Highlights Racial Disparities
Background/Purpose: SLE is an independent risk factor for premature cardiovascular disease (CVD) and afflicts African Americans (AA’s) 3 times more than whites. Two predominantly white…Abstract Number: 2059 • 2019 ACR/ARP Annual Meeting
Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases
Background/Purpose: Subjects with rheumatic diseases have an increased risk of cardiovascular (CV) morbimortality. Hypertension (HTN) is a key modifiable risk factor for CV events. A…Abstract Number: 900 • 2019 ACR/ARP Annual Meeting
Serum Urate Lowering with Allopurinol Improves Endothelial Function in Young Adults
Background/Purpose: An effect of serum urate on vascular endothelium has been postulated as a mechanism for its association with hypertension and cardiovascular disease. Prior studies…Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…Abstract Number: 921 • 2019 ACR/ARP Annual Meeting
Indicators of Actionable Levels of Atherosclerosis in RA Patients Who Appear to Have Low or Intermediate Atherosclerotic Cardiovascular Risk Based on Standard Risk Algorithms
Background/Purpose: In the general population, statins reduces atherosclerotic cardiovascular disease (ASCVD) events in those with a computed tomography (CT)-assessed coronary artery calcium (CAC) score ≥100…
- 1
- 2
- 3
- …
- 38
- Next Page »